Fig. 5
AurA modulates glioblastoma cell cytoskeleton and CDC42-dependent migration in response to CXCL12 stimulation. Western-blot analysis and relative quantification of Acetylated Tubulin/Tubulin (a), Vimentin/Actin (b), F-Actin/Actin (c) in U87MG cells after Alisertib treatment (48 h, 5 nM) and CXCL12 stimulation (16 h, 12.5 nM) (n = 3). d Western-blot analysis and relative quantification of CDC42/Actin in U87MG and GBM1 cells after Alisertib treatment (48 h, 5 nM) and CXCL12 stimulation (16 h, 12.5 nM) (n = 3). e Boyden’s chambers migration assays after CXCL12 stimulation (16 h, 500 nM) of U87MG and GBM1 cells after Alisertib (48 h, 5 nM) and ML141 (24 h, 10 μM) treatments (n = 3). Graphs are mean values ± SD and are representative of three independent experiments, *p < 0.05, **p < 0.01, ***p < 0.001 (2-way ANOVA corrected by post-tests if appropriate)
